Edition:
United States

H Lundbeck A/S (HLUKF.PK)

HLUKF.PK on OTC Markets Group

57.75USD
--
Change (% chg)

-- (--)
Prev Close
$57.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
129
52-wk High
$64.93
52-wk Low
$32.10

Select another date:

Mon, Sep 11 2017

Israel's Teva Pharma appoints H Lundbeck's Kare Schultz as CEO

Sept 11 Teva Pharmaceutical Industries Ltd named H Lundbeck A/S Chief Executive Kare Schultz as its new CEO and president, the Israel-based drugmaker said on Monday.

UPDATE 1-Lundbeck raises outlook, awaits generic competition

* Raises profit outlook for 5th consecutive quarter * Q2 results beat forecasts * Q2 helped by lack of generic competition (Adds CEO, analyst, share price background) COPENHAGEN, Aug 9 Danish neuroscience drug specialist Lundbeck on Wednesday raised its profit outlook for the fifth quarter in a row after posting strong second-quarter results, helped by demand for older medicines and lack of generic competition. Lundbeck's share price has nearly tripled

BRIEF-Lundbeck H1 revenue up at DKK 8.49 billion

* LUNDBECK REPORTS 13% REVENUE GROWTH AND A DOUBLING OF EBIT IN FIRST HALF OF 2017

Danish drugmaker Lundbeck raises 2017 profit outlook

Aug 9 Danish neuroscience drug specialist Lundbeck raised its profit and sales outlook for the year on Wednesday after posting strong second-quarter results, helped by demand for older medicines.

BRIEF-Lundbeck: Abilify Maintena (aripiprazole) for extended-release injectable suspension approved by the U.S. FDA for maintenance monotherapy treatment of bipolar I disorder

* ABILIFY MAINTENA® (ARIPIPRAZOLE) FOR EXTENDED-RELEASE INJECTABLE SUSPENSION APPROVED BY U.S. FDA FOR MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Lundbeck, Takeda receive CRL from FDA for Trintellix (vortioxetine) sNDA

* Lundbeck and Takeda receive complete response letter from the FDA for Trintellix® (vortioxetine) sNDA

BRIEF-Lundbeck obtains rights to research in Alzheimer's disease

* SIGNS DEAL WITH BIOTECH COMPANY IMMUNOBRAIN CHECKPOINT, INC. (IBC) FOR RIGHTS TO RESEARCH IN TREATMENT OF ALZHEIMER'S DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

UPDATE 1-Lundbeck raises earnings guidance for the fourth time in 12 months

May 10 Danish drugmaker Lundbeck raised its financial guidance for the fourth time in 12 months as sales of its anti-epileptic drug Sabril was not dented by copycat competition, as Lundbeck had expected, its chief executive said on Wedneday.

BRIEF-Lundbeck Q1 EBIT at DKK 1.01 Billion, above expectations

* 2017 GUIDANCE RAISED BASED ON STRONG REVENUE GROWTH AND IMPROVED PROFITABILITY

BRIEF-Lundbeck enters a conditional agreement to sell part of its headquarters

* LUNDBECK ENTERS A CONDITIONAL AGREEMENT AND DIVESTS PART OF ITS HEADQUARTERS IN COPENHAGEN AND EXPECTS TO RAISE ITS FINANCIAL GUIDANCE BY DKK 200 MILLION

Select another date: